Vivos Inc. Submits the Application to the FDA for Authority to Initiate Human Clinical Trials
June 28, 2024 10:15 ET
|
Vivos Inc.
Richland WA, June 28, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc. filed the application for an Investigational Device Exemption (“IDE”). The filing was an amendment, addressing...
Vivos Inc Files a New Patent on Alternate Particles for Precision Radionuclide Therapy
January 11, 2023 09:30 ET
|
Vivos Inc.
Richland WA, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc announced today that the company filed a utility patent application on a range of particles for precision...
Vivos Inc Files a New Patent on Precision Radionuclide Therapy Support System Equipment
January 03, 2023 09:30 ET
|
Vivos Inc.
Richland WA, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc announced today that they filed a provisional patent application on the system equipment to support precision...
Vivos Inc. Announces a New IsoPet® Precision Radionuclide Therapy Regional Clinic for Equine Therapy
August 16, 2022 09:30 ET
|
Vivos Inc.
Richland WA, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to report that it just certified the New England Equine Practice in Patterson, NY to administer...
Vivos Inc. Provides Intellectual Property Protection Update
May 12, 2022 09:30 ET
|
Vivos Inc.
Richland WA, May 12, 2022 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to report that it expanded its intellectual property protection on several fronts. Our patent team filed...
Vivos Inc. Enhances its Intellectual Property Protection
February 24, 2022 09:30 ET
|
Vivos Inc.
Richland WA, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to report that it filed its particle patent in several countries. Our new patent team filed the...
Vivos Inc. Provides 2021 Recap and Outlines 2022 Objectives
January 24, 2022 09:30 ET
|
Vivos Inc.
Richland WA, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), provides 2021 recap and outlines future objectives. Vivos’ CEO, Dr. Mike Korenko stated, “as we begin 2022, we wanted to...
Vivos Inc Obtains Feedback from the FDA on Clinical Testing of RadioGel™
December 02, 2021 09:30 ET
|
Vivos Inc.
Richland WA, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), on November 30 Vivos Inc met with the Food and Drug Administration to obtain suggestions on improving the current draft of...
Vivos Inc Announces Johns Hopkins University (Veterinary Clinical Trials Network) is a New Regional Clinic for Isopet®
November 23, 2021 09:30 ET
|
Vivos Inc.
This replaces and corrects the press release from November 22. Johns Hopkins (VCTN) Veterinary Clinical Trials Network is our teaming partner not the Center for Image Guided Animal Therapy (CIGAT). ...
Vivos Inc Enhances Radiogel™ Manufacturing Process
May 24, 2021 09:30 ET
|
Vivos Inc.
Richland WA, May 24, 2021 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), During the past few months Vivos has made significant enhancements to the manufacturing process for Radiogel™. These...